This prospective trial evaluated first-line osimertinib combined with platinum and etoposide in patients with EGFR-mutant lung adenocarcinoma harboring concurrent TP53 and RB1 alterations, who are at high risk for histological transformation. Despite incorporating SCLC-directed chemotherapy upfront, nearly half of the patients (5 of 11) experienced SCLC transformation, yielding a median progression-free survival of 11 months and a median overall survival of 33 months. Genomic and single-cell transcriptomic analyses revealed pronounced phenotypic plasticity towards SCLC, mesenchymal, and squamous lineages. These lineage shifts were driven by progressive disruption of the RB pathway and chromatin remodeling, which were further amplified under the selective pressure of osimertinib treatment.
This retrospective cohort study of 1,095 patients with metastatic pancreatic ductal adenocarcinoma (PDAC) demonstrates that the pattern of metastatic spread is strongly linked to clinical outcome and genomic detection. Patients with lung-only metastases had a significantly prolonged median overall survival of 57.6 months compared to roughly 19.5 months in patients with liver-involved disease. Tissue genomic profiling identified lower TP53 mutation frequencies and higher GNAS mutation rates in non-liver and lung-only metastases. Crucially, liquid biopsy (n = 240) showed markedly lower detection rates for KRAS (10%) and TP53 (23%) in lung-only disease, underscoring that tissue-based sequencing must be prioritized in these patients to guide KRAS-directed therapeutic decisions.
This study employed a deep learning-based graph neural network model to identify genes and pathogenic genetic variations driving gastric cancer pathogenesis. Researchers focused on tumor suppressor proteins exhibiting both dysregulated expression and high mutation propensity. The model identified 1,886 relevant genes, with TP53, ERBB2, CDH1, and APC emerging as prominent hub genes. Missense and nonsense variants in TP53, CDH1, and APC were validated, affecting post-translational modification sites and correlating with altered patient survival. The study also highlighted EZH2 and miR-129-5p as key regulators and the dysregulation of oncogenes like CCNE1/2 and FGFR2.
This study analyzed a cohort of 1,254 patients with biliary tract cancer to assess the utility of targeted NGS molecular profiling. It revealed that 59% of patients harbored at least one OncoKB alteration, and 32.2% had level 1/2 alterations, with varying frequencies across tumor locations. Targeted therapies were associated with improved progression-free survival but not overall survival. The study also identified co-occurring alterations and acquired resistance mechanisms, such as ERBB2 loss or alterations in the RAS, MEK, MET, MYC, and CDKN2A pathways. These findings highlight genomic heterogeneity and the importance of precision medicine in informing future drug development efforts.
This study characterized the molecular subtypes and the spectrum of POLE gene mutations in a South Indian cohort of endometrial carcinoma patients. Using the ProMisE classification, researchers identified four molecular subgroups: POLE ultra-mutated, MMR-deficient, p53-abnormal, and no specific molecular profile (NSMP). POLE gene sequencing revealed known variants like V411L, as well as several non-hotspot variants, six of which were unique to this cohort and four predicted to be oncogenic. p53-abnormal tumors exhibited a more aggressive phenotype and increased chemotherapy use. The integration of molecular profiling with histopathology is deemed crucial for enhancing endometrial carcinoma classification and prognostic assessment.
This SUMMIT basket trial study evaluated the efficacy of neratinib alone or in combination with trastuzumab in patients with HER2-mutant metastatic triple-negative breast cancer (TNBC). Results showed confirmed objective response rates of 40% for neratinib alone and 35.3% for the combination, with median progression-free survival times of 2.89 and 6.24 months, respectively. Circulating tumor DNA (ctDNA) monitoring correlated decreases in HER2 mutation variant allele frequencies with treatment response and identified the emergence of resistance mutations. The neratinib and trastuzumab combination appears to prolong responses compared to neratinib alone, offering a novel approach for biomarker-defined metastatic TNBC.
The Phase II ORCHARD study investigated resistance mechanisms to first-line osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Utilizing next-generation sequencing (NGS) on both tissue and plasma samples, the study characterized the molecular profile of tumors after progression. Resistance alterations were detected in 87% of samples, often multiple, involving genes such as TP53, MDM2/4, PI3K, SOX2, and MYC. These findings highlight the heterogeneity of resistance and provide a rationale for exploring combination therapies to improve patient outcomes.
This study conducted comprehensive genomic profiling on 39 cases of pleomorphic liposarcoma (PLPS) to characterize its molecular landscape and compare it with other complex sarcomas like UPS and MFS. Analyses revealed that TP53 (87%) and RB1 (51%) alterations are the most frequent in PLPS, and significantly more common than in UPS and MFS. MYC amplification was associated with significantly shorter overall survival, suggesting a prognostic role. Furthermore, correlations were established between gene alterations and morphological features, including CYSLTR2 alterations in cases with predominant pleomorphic lipoblasts. These findings highlight the molecular distinctiveness of PLPS and provide insights for future diagnostic and therapeutic strategies.
Cervical adenocarcinoma is linked to poorer survival and reduced response to immunotherapy. This study identified STK11 alterations, including mutations and focal deletions, as a distinct feature of HPV-positive cervical adenocarcinomas, affecting 23% of these tumors. These alterations are associated with a younger age at diagnosis, poorer overall survival, and inferior outcomes following immune checkpoint inhibitor therapy. Comprehensive genomic analyses revealed complex structural rearrangements involving chromosome 19p and STK11. These findings define an aggressive molecular subgroup and have implications for molecular classification and future targeted therapeutic strategies.
This prospective observational study investigated the prognostic value of circulating tumor DNA (ctDNA)-derived tumor fraction (TFx) and copy-number alterations (CNAs) in 78 patients with metastatic castration-resistant prostate cancer (mCRPC) receiving tandem [225Ac]Ac-/[177Lu]Lu-PSMA-617 radioligand therapy. Findings revealed that ctDNA-derived TFx serves as a dynamic biomarker for treatment response and progression risk, with a significantly increased risk of progression (HR 4.9) when modeled as a time-dependent variable. Furthermore, a high CNA burden was associated with shorter median overall survival (8.3 vs 13.8 months). The study identified recurrent CNAs affecting key tumor suppressor genes and highlighted the potential of these ctDNA-based biomarkers for clinical stratification and real-time monitoring.
Zhonghua zhong liu za zhi [Chinese journal of oncology] ·
This study investigated the clinical value of dynamic monitoring of circulating tumor DNA (ctDNA) in 94 patients with advanced esophageal squamous cell carcinoma (ESCC) receiving sintilimab. The findings indicate that the ctDNA-based molecular tumor burden index (mTBI) serves as a sensitive, real-time biomarker for evaluating immunotherapy efficacy. Patients achieving ctDNA clearance or having a low mTBI after two treatment cycles demonstrated significantly delayed tumor progression and improved overall survival. Dynamic mTBI monitoring showed high consistency with concurrent imaging assessments, suggesting its utility for personalized treatment management.
This study characterized the prevalence of KRAS G12C mutations in genitourinary malignancies, an area with limited data despite the approval of targeted therapies. Comprehensive genomic profiling was performed on over 13,000 samples of renal clear cell carcinomas, urothelial bladder carcinomas, and prostate acinar adenocarcinomas. Results indicated that KRAS G12C mutations are infrequent in these tumors, with an incidence of 0% in renal carcinomas, 0.6% in urothelial bladder carcinomas, and less than 0.01% in prostate adenocarcinomas. Despite their low frequency, these mutations represent an emerging therapeutic target, warranting further investigation, particularly in basket trials for patients harboring this actionable alteration.
This study represents the largest to date evaluating the impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes in EGFR-mutant non-small cell lung cancer (NSCLC) patients receiving front-line osimertinib. Researchers analyzed data from patients within a U.S. clinical-genomic database. The findings indicated that the presence of either the EGFR L858R mutation or a TP53 co-mutation independently predicted inferior real-world progression-free survival (rwPFS) and overall survival (OS). Patients with both unfavorable alterations (EGFR L858R and mutant TP53) experienced the shortest survival, with a median rwPFS of 10.1 months and a median OS of 21.3 months. This risk stratification could assist in identifying patients who might benefit from novel trials or intensified therapies.
This retrospective study compared the clinicopathological features of stage I-II oral squamous cell carcinoma (OSCC) in adolescents and young adults (AYAs) versus older patients. OSCCs in AYAs are more frequently located on the tongue and exhibit distinct histological patterns, including an abnormal TP53 immunophenotype. Although AYAs demonstrate significantly better overall and disease-free survival, a depth of invasion (DOI) greater than 5 mm is a major prognostic indicator for distant metastasis and poorer survival within this group. Other factors such as clinical stage, tumor thickness, and tumor budding may also predict the risk of postoperative lymph node metastasis. Tested molecular markers did not provide robust prognostic stratification.
This study developed and evaluated an optimized intramuscular patient-derived xenograft (PDX) platform for gastric cancer. The model achieved a high engraftment rate of 71.7%, significantly exceeding conventional methods. Researchers utilized whole exome sequencing to identify divergent driver mutations between fast- and slow-growing tumors. The findings suggest that PDX-guided chemotherapy selection is associated with improved progression-free survival, and that driver mutation profiles can serve as prognostic biomarkers.
This Japanese real-world study investigated comprehensive genomic profiling and tumor mutational burden (TMB) in parathyroid carcinoma, a rare endocrine malignancy. Among 25 patients, 28% exhibited elevated TMB (≥ 10 mut/Mb), with frequent alterations observed in CDC73, TP53, and MEN1 genes. POLE alterations and microsatellite instability (MSI-high) were also identified in some cases. These findings highlight the molecular heterogeneity of the disease and the value of genomic profiling for uncovering potential therapeutic opportunities.
This study investigated the TP53 mutation landscape in oral squamous cell carcinoma (OSCC) and its association with patient survival. Using next-generation sequencing on 124 samples, pathogenic TP53 mutations were detected in 65% of patients, encompassing 75 distinct variant patterns. Patients harboring these mutations exhibited significantly shorter cancer-specific survival, particularly those with advanced-stage (III/IV) disease. Truncating or splice mutations were associated with an even worse prognosis. These findings highlight the importance of TP53-based molecular classification for developing novel precision strategies against OSCC.
This real-world study analyzed the genomic landscape of GNAQ and GNA11 mutations in 5,416 patients with metastatic solid tumors. It revealed that these mutations, while known in uveal melanoma, are also present in other cancers such as colorectal, melanoma, and gastric cancer. An immunogenic subgroup, characterized by non-hotspot mutations and high TMB or MSI, was identified and associated with potential benefit from immune checkpoint inhibitors. Canonical hotspot mutations, conversely, were predominant in TMB-low/MSS tumors. These findings highlight the importance of differentiating driver mutations from bystander mutations to guide therapeutic strategies.
This retrospective study investigated the clinical, surgical, and molecular characteristics and outcomes of 52 adult patients with H3 K27-altered diffuse midline glioma (DMG) treated with surgical resection. The median overall survival was 17.8 months. Genomic profiling revealed a distinct molecular landscape dominated by H3F3A mutations, frequently co-occurring with TP53 mutations, and a significant enrichment of mutations within the RTK/RAS/PI3K signaling pathway, involving NF1, FGFR1, and PIK3CA. Postoperative adjuvant radiotherapy combined with temozolomide emerged as the sole independent protective factor for overall survival. While maximal safe resection is considered essential, molecular targeted therapies did not achieve independent statistical significance.
This study characterized the genomic landscape of leiomyosarcoma, a rare and aggressive tumor, by analyzing a large dataset from the AACR Project GENIE. Researchers examined over 1,000 tumor samples, identifying the most frequent somatic mutations and copy number alterations. TP53, RB1, and ATRX were the most commonly altered genes, with homozygous deletions of RB1 and TP53, and MAP2K4 amplifications. The study also highlighted enriched IGF2 and AXIN1 alterations in metastatic samples, suggesting their potential role in disease progression. These findings enhance the understanding of leiomyosarcoma biology and could guide future precision oncology strategies.
This study investigated additional genetic alterations in MET-amplified gastric cancers (GCs), which are associated with poor prognosis and limited response to targeted therapies. Researchers found that MET amplification is frequently accompanied by co-amplifications of other oncogenes located on chromosome 7, such as BRAF, CDK6, and EGFR, in 54% of cases. These co-amplifications exhibit significant intra- and intertumoral heterogeneity. This complex heterogeneity may explain the diagnostic and therapeutic challenges, subclonal evolution, and the failure of targeted therapies in MET-amplified GCs.
This international study aimed to identify genetic prognostic biomarkers in a specific subgroup of intermediate-risk neuroblastoma patients, over 18 months old, without MYCN amplification, with localized unresectable or stage 3 tumors, and unfavorable histology, who experience poorer outcomes. Researchers analyzed chromosomal copy number alterations, next-generation DNA sequencing, telomere maintenance mechanisms, and gene expression. The findings revealed that oncogene amplifications, p53 pathway alterations, and typical segmental chromosomal aberrations (tSCAs) are independent prognostic markers associated with significantly reduced event-free and overall survival. These discoveries suggest that these patients might benefit from intensified or alternative treatments.
This study assesses the performance of in silico prediction tools for genetic variant curation within a panel of cancer predisposition genes. Researchers applied ClinGen SVI Working Group recommended thresholds and AlphaMissense predictions to variants in genes such as BRCA1, BRCA2, TP53, TERT, and ATM, which have established pathogenicity or benignity. The findings indicated insufficient sensitivity for pathogenic TERT variants and benign TP53 variants. The study emphasizes that the performance of these tools can be gene-specific and is influenced by their training datasets. Consequently, it is crucial to validate these tools for individual genes, especially for missense variants.
This prospective study evaluated gene expression profiling of seven genes (EGFR, FGFR2, PIK3CA, PTEN, SMAD4, STK11, TP53) in cell-free RNA (cfRNA) from exhaled breath condensate (EBC) in patients with advanced lung adenocarcinoma. Results indicated that PIK3CA showed the best diagnostic performance in distinguishing patients from healthy controls. High expression of FGFR2 and PIK3CA was associated with significantly shorter overall survival, highlighting their prognostic relevance. EGFR expression demonstrated a strong correlation between EBC and plasma, and low EGFR expression was linked to longer survival in patients receiving chemotherapy alone. This non-invasive EBC-based approach offers potential for molecular characterization and patient stratification.
This retrospective study analyzed 120 cases of lung adenocarcinoma (LUAD) with malignant serous effusions (MSE) to characterize their clinicopathologic, molecular, and prognostic features. Pleural effusions were most common, but pericardial involvement was associated with the shortest overall survival. Molecular profiling revealed TP53 mutations and actionable alterations in genes such as EGFR, KRAS, BRAF, ALK, and ROS1. NKX2-1 (TTF-1) negativity and the absence of actionable alterations were independent adverse prognostic factors, with dual NKX2-1/CD274 (PD-L1) negativity defining the poorest prognosis subgroup. Immunotherapy-based regimens and tyrosine kinase inhibitors showed varying survival benefits.
Otolaryngologia polska = The Polish otolaryngology ·
This study analyzed the genomic profile of 480 patients with metastatic adenocarcinoma of unknown primary (ACUP) using the FoundationOne CDx platform. The most frequent mutations included TP53, KRAS, and CDKN2A. Results showed that GNAS and PIK3CA mutations were associated with better overall survival. Conversely, ARID1A and NOTCH1 alterations were linked to a worse prognosis. These findings highlight the significance of specific genomic alterations as prognostic markers in ACUP.
The FIGO staging system for endometrial cancer underwent a significant revision in 2023, incorporating refined anatomical criteria and molecular determinants. This update aims to optimize adjuvant treatment selection by maximizing therapeutic benefits while minimizing harm. Molecular subgroups include POLEmut, p53abn, MMRd, and NSMP. The 2025 ESGO-ESTRO-ESP recommendations further enhance this framework by mandating estrogen receptor (ER) assessment within the NSMP category, identifying early-stage disease with an increased risk of recurrence and mortality.
This large genomic analysis of 2901 endometrial carcinomas refines molecular classification by addressing several clinical questions. The study confirms that all four mismatch repair genes (MLH1, MSH2, MSH6, PMS2) confer an equivalently favorable prognosis, validating dMMR status as a class-level prognostic designation. It demonstrates that the exceptional survival benefit associated with POLE-ultramutated tumors is confined to canonical exonuclease-domain hotspot mutations, excluding variants of uncertain significance. Finally, patients with TP53 mutations and high copy-number instability (CNH) are identified as having the most urgent unmet therapeutic need.
This study evaluates the efficacy of qPCR for HER2 status assessment in invasive ductal carcinoma of the breast, comparing it with IHC and FISH. Results demonstrate high concordance between qPCR and FISH, particularly in resolving equivocal IHC 2+ cases. Furthermore, exploratory genomic profiling via WES on high-risk subtypes (HER2 3+ and TNBC) revealed somatic mutations in key genes such as TP53, BRCA1, and MYCN, as well as AR expression in TNBC. These findings highlight qPCR’s potential as an accurate diagnostic tool and provide a foundation for future precision oncology strategies.
Somatic mutations in GC-rich promoter regions are significant drivers of cancer, yet their detection is challenging due to poor sequencing coverage in these areas. This study introduces a hybrid capture assay optimized for over 3000 cancer gene promoters, enabling deep sequencing of these complex regions. This method facilitates the discovery of reliable point mutations, short insertions/deletions, copy number variants, and mutational signatures. The assay nominated candidate noncoding driver mutations in CDK4, SMAD3, and GATA3 in breast cancer, paving the way for future functional follow-up.
This prospective observational study assessed the utility of circulating tumor DNA (ctDNA) for mutational profiling and dynamic monitoring in 33 patients with metastatic colorectal cancer receiving palliative chemotherapy. ctDNA was detected in most patients at baseline, revealing frequent mutations in APC, TP53, KRAS, and PIK3CA. Good concordance was observed between plasma ctDNA profiles and tissue data. Longitudinal analysis showed the emergence of acquired mutations, particularly RAS mutations under anti-EGFR therapy, and correlated high ctDNA levels with shorter overall survival. These findings highlight ctDNA’s potential to guide personalized treatment strategies and monitor resistance.
Papadopoulou E, Stathoulopoulou M, Matiatou M, et al.
Cancer genomics & proteomics ·
This study investigated the associations between clinicopathological characteristics and genetic alterations in breast cancer, focusing on how clinical and pathological variables influence the actionability of Next Generation Sequencing (NGS) data. Among 227 breast cancer patients, comprehensive genomic profiling revealed that a vast majority (95.6%) harbored at least one oncogenic alteration. Subtype-specific patterns were identified, with an enrichment of PIK3CA and ESR1 alterations in HR+/HER2- tumors, and a predominance of TP53 in triple-negative breast cancer. The study highlights that NGS-based genomic profiling identifies clinically actionable alterations in over half of breast cancer patients, particularly in the HR+/HER2- subtype, and supports its routine implementation, especially for metastatic HER2-negative breast cancer.